Chemoprevention of breast cancer

Area of Science:

• Oncology
• Pharmacology
• Preventive Medicine

Background:

• Estrogen receptor-positive breast cancer risk can be reduced using prophylactic agents.
• Tamoxifen has demonstrated efficacy in preventing approximately half of these cancer cases.
• Improving efficacy and reducing side effects remain key challenges in breast cancer prevention.

Purpose of the Study:

• To evaluate the efficacy and side-effect profiles of newer agents for breast cancer prevention.
• To compare selective estrogen receptor modulators (SERMs) and aromatase inhibitors with existing therapies.
• To identify potential new agents for estrogen receptor-negative breast cancer.

Main Methods:

• Review of clinical trials involving tamoxifen, raloxifene, and aromatase inhibitors.
• Analysis of efficacy data regarding breast cancer risk reduction.
• Assessment of reported side-effect profiles for different prophylactic agents.

Main Results:

• Raloxifene shows efficacy comparable to tamoxifen but with a better side-effect profile.
• Aromatase inhibitors are under investigation in Phase III trials and suggest potential for 70-80% prevention of receptor-positive breast cancers.
• Current agents are primarily effective for estrogen receptor-positive breast cancer, with ongoing research for receptor-negative types.

Conclusions:

• Selective estrogen receptor modulators and aromatase inhibitors represent promising advancements in breast cancer prevention.
• These newer agents offer improved side-effect profiles and potentially higher efficacy rates.
• Further research is necessary to develop effective preventive strategies for estrogen receptor-negative breast cancer.